Hillemanns Peter, Kampers Johanna, Hachenberg Jens, Jentschke Matthias
Klinik für Frauenheilkunde und Geburtshilfe, Medizinische Hochschule Hannover (MHH), Carl-Neuberg-Str. 1, 30625, Hannover, Deutschland.
Internist (Berl). 2021 Aug;62(8):816-826. doi: 10.1007/s00108-021-01102-0. Epub 2021 Jul 14.
Vaccination against human papillomavirus (HPV), which has been proven to be highly effective and safe, is recommended as part of standard vaccination by the German Standing Committee on Vaccination (STIKO) for 9‑ to 14-year-old girls and boys. Up to 90% of cervical cancer and its precancerous lesions can be prevented with timely vaccination (before first intercourse). In addition, the effectiveness extends to the primary prevention of HPV-associated neoplasms of the vulva, vagina, anus, penis and oropharynx. The HPV vaccination is the focus of the global initiative of the WHO calling on German health policymakers to significantly increase the immunization coverage of the German population, which is currently only 45-60%. Due to the high immunogenicity and the convincing long-term effects, the goals of eliminating cervical cancer and significantly reducing other HPV-associated cancers are theoretically achievable.
人乳头瘤病毒（HPV）疫苗已被证明高度有效且安全，德国疫苗接种常设委员会（STIKO）建议将其作为9至14岁女孩和男孩标准疫苗接种的一部分。及时接种疫苗（首次性交前）可预防高达90%的宫颈癌及其癌前病变。此外，该疫苗的有效性还扩展到对外阴、阴道、肛门、阴茎和口咽HPV相关肿瘤的一级预防。HPV疫苗接种是世界卫生组织全球倡议的重点，该倡议呼吁德国卫生政策制定者大幅提高德国人口的免疫覆盖率，目前德国的免疫覆盖率仅为45%-60%。由于高免疫原性和令人信服的长期效果，消除宫颈癌和显著减少其他HPV相关癌症的目标在理论上是可以实现的。
